Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

Susanna Esposito, Susan Tansey, Allison Thompson, Ahmad Razmpour, John Liang, Thomas R. Jones, Giuseppe Ferrera, Alessandro Maida, Gianni Bona, Caterina Sabatini, Lorenza Pugni, Emilio A. Emini, William C. Gruber, Daniel A. Scott, Nicola Principi

Research output: Contribution to journalArticle

Abstract

A 13-valent pneumococcal conjugate vaccine (PCV13) has been developed to improve protection against pneumococcal disease beyond that possible with the licensed 7-valent vaccine (PCV7). This study compared the safety and immunogenicity of PCV13 with those of PCV7 when given as part of the pediatric vaccination schedule recommended in Italy. A total of 606 subjects were randomly assigned to receive either PCV13 or PCV7 at 3, 5, and 11 months of age; all subjects concomitantly received diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B (DTaP-HBV-IPV/Hib) vaccine. Vaccine reactions were monitored. Antibody responses to DTaP-HBV-IPV/Hib antigens, serotype-specific anticapsular polysaccharide IgG responses, and antipneumococcal opsonophagocytic assay (OPA) activity were measured 1 month after the two-dose primary series and 1 month after the toddler dose. Overall, the safety profile of PCV13 was similar to that of PCV7. The response to DTaP-HBV-IPV/Hib antigens was substantially the same with both PCV13 and PCV7. PCV13 elicited antipneumococcal capsular IgG antibodies to all 13 vaccine serotypes, with notable increases in concentrations seen after the toddler dose. Despite a lower immunogenicity for serotypes 6B and 23F after the primary series of PCV13, responses to the seven common serotypes were comparable between the PCV13 and PCV7 groups when measured after the toddler dose. PCV13 also elicited substantial levels of OPA activity against all 13 serotypes following both the infant series and the toddler dose. In conclusion, PCV13 appeared comparable to PCV7 in safety profile and immunogenicity for common serotypes, demonstrated functional OPA responses for all 13 serotypes, and did not interfere with immune responses to concomitantly administered DTaP-HBV-IPV/Hib vaccine.

Original languageEnglish
Pages (from-to)1017-1026
Number of pages10
JournalClinical and Vaccine Immunology
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Assays
Vaccines
Safety
Immunoglobulin G
Antigens
Pediatrics
Antibodies
Haemophilus influenzae type b
Polysaccharides
Diphtheria
Whooping Cough
Haemophilus influenzae
Tetanus
Poliomyelitis
Serogroup
13-valent pneumococcal vaccine
Hepatitis B
Italy

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. / Esposito, Susanna; Tansey, Susan; Thompson, Allison; Razmpour, Ahmad; Liang, John; Jones, Thomas R.; Ferrera, Giuseppe; Maida, Alessandro; Bona, Gianni; Sabatini, Caterina; Pugni, Lorenza; Emini, Emilio A.; Gruber, William C.; Scott, Daniel A.; Principi, Nicola.

In: Clinical and Vaccine Immunology, Vol. 17, No. 6, 06.2010, p. 1017-1026.

Research output: Contribution to journalArticle

Esposito, S, Tansey, S, Thompson, A, Razmpour, A, Liang, J, Jones, TR, Ferrera, G, Maida, A, Bona, G, Sabatini, C, Pugni, L, Emini, EA, Gruber, WC, Scott, DA & Principi, N 2010, 'Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers', Clinical and Vaccine Immunology, vol. 17, no. 6, pp. 1017-1026. https://doi.org/10.1128/CVI.00062-10
Esposito, Susanna ; Tansey, Susan ; Thompson, Allison ; Razmpour, Ahmad ; Liang, John ; Jones, Thomas R. ; Ferrera, Giuseppe ; Maida, Alessandro ; Bona, Gianni ; Sabatini, Caterina ; Pugni, Lorenza ; Emini, Emilio A. ; Gruber, William C. ; Scott, Daniel A. ; Principi, Nicola. / Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. In: Clinical and Vaccine Immunology. 2010 ; Vol. 17, No. 6. pp. 1017-1026.
@article{4f2ff04ddab440c68b639c5b61e60c3b,
title = "Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers",
abstract = "A 13-valent pneumococcal conjugate vaccine (PCV13) has been developed to improve protection against pneumococcal disease beyond that possible with the licensed 7-valent vaccine (PCV7). This study compared the safety and immunogenicity of PCV13 with those of PCV7 when given as part of the pediatric vaccination schedule recommended in Italy. A total of 606 subjects were randomly assigned to receive either PCV13 or PCV7 at 3, 5, and 11 months of age; all subjects concomitantly received diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B (DTaP-HBV-IPV/Hib) vaccine. Vaccine reactions were monitored. Antibody responses to DTaP-HBV-IPV/Hib antigens, serotype-specific anticapsular polysaccharide IgG responses, and antipneumococcal opsonophagocytic assay (OPA) activity were measured 1 month after the two-dose primary series and 1 month after the toddler dose. Overall, the safety profile of PCV13 was similar to that of PCV7. The response to DTaP-HBV-IPV/Hib antigens was substantially the same with both PCV13 and PCV7. PCV13 elicited antipneumococcal capsular IgG antibodies to all 13 vaccine serotypes, with notable increases in concentrations seen after the toddler dose. Despite a lower immunogenicity for serotypes 6B and 23F after the primary series of PCV13, responses to the seven common serotypes were comparable between the PCV13 and PCV7 groups when measured after the toddler dose. PCV13 also elicited substantial levels of OPA activity against all 13 serotypes following both the infant series and the toddler dose. In conclusion, PCV13 appeared comparable to PCV7 in safety profile and immunogenicity for common serotypes, demonstrated functional OPA responses for all 13 serotypes, and did not interfere with immune responses to concomitantly administered DTaP-HBV-IPV/Hib vaccine.",
author = "Susanna Esposito and Susan Tansey and Allison Thompson and Ahmad Razmpour and John Liang and Jones, {Thomas R.} and Giuseppe Ferrera and Alessandro Maida and Gianni Bona and Caterina Sabatini and Lorenza Pugni and Emini, {Emilio A.} and Gruber, {William C.} and Scott, {Daniel A.} and Nicola Principi",
year = "2010",
month = "6",
doi = "10.1128/CVI.00062-10",
language = "English",
volume = "17",
pages = "1017--1026",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

AU - Esposito, Susanna

AU - Tansey, Susan

AU - Thompson, Allison

AU - Razmpour, Ahmad

AU - Liang, John

AU - Jones, Thomas R.

AU - Ferrera, Giuseppe

AU - Maida, Alessandro

AU - Bona, Gianni

AU - Sabatini, Caterina

AU - Pugni, Lorenza

AU - Emini, Emilio A.

AU - Gruber, William C.

AU - Scott, Daniel A.

AU - Principi, Nicola

PY - 2010/6

Y1 - 2010/6

N2 - A 13-valent pneumococcal conjugate vaccine (PCV13) has been developed to improve protection against pneumococcal disease beyond that possible with the licensed 7-valent vaccine (PCV7). This study compared the safety and immunogenicity of PCV13 with those of PCV7 when given as part of the pediatric vaccination schedule recommended in Italy. A total of 606 subjects were randomly assigned to receive either PCV13 or PCV7 at 3, 5, and 11 months of age; all subjects concomitantly received diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B (DTaP-HBV-IPV/Hib) vaccine. Vaccine reactions were monitored. Antibody responses to DTaP-HBV-IPV/Hib antigens, serotype-specific anticapsular polysaccharide IgG responses, and antipneumococcal opsonophagocytic assay (OPA) activity were measured 1 month after the two-dose primary series and 1 month after the toddler dose. Overall, the safety profile of PCV13 was similar to that of PCV7. The response to DTaP-HBV-IPV/Hib antigens was substantially the same with both PCV13 and PCV7. PCV13 elicited antipneumococcal capsular IgG antibodies to all 13 vaccine serotypes, with notable increases in concentrations seen after the toddler dose. Despite a lower immunogenicity for serotypes 6B and 23F after the primary series of PCV13, responses to the seven common serotypes were comparable between the PCV13 and PCV7 groups when measured after the toddler dose. PCV13 also elicited substantial levels of OPA activity against all 13 serotypes following both the infant series and the toddler dose. In conclusion, PCV13 appeared comparable to PCV7 in safety profile and immunogenicity for common serotypes, demonstrated functional OPA responses for all 13 serotypes, and did not interfere with immune responses to concomitantly administered DTaP-HBV-IPV/Hib vaccine.

AB - A 13-valent pneumococcal conjugate vaccine (PCV13) has been developed to improve protection against pneumococcal disease beyond that possible with the licensed 7-valent vaccine (PCV7). This study compared the safety and immunogenicity of PCV13 with those of PCV7 when given as part of the pediatric vaccination schedule recommended in Italy. A total of 606 subjects were randomly assigned to receive either PCV13 or PCV7 at 3, 5, and 11 months of age; all subjects concomitantly received diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B (DTaP-HBV-IPV/Hib) vaccine. Vaccine reactions were monitored. Antibody responses to DTaP-HBV-IPV/Hib antigens, serotype-specific anticapsular polysaccharide IgG responses, and antipneumococcal opsonophagocytic assay (OPA) activity were measured 1 month after the two-dose primary series and 1 month after the toddler dose. Overall, the safety profile of PCV13 was similar to that of PCV7. The response to DTaP-HBV-IPV/Hib antigens was substantially the same with both PCV13 and PCV7. PCV13 elicited antipneumococcal capsular IgG antibodies to all 13 vaccine serotypes, with notable increases in concentrations seen after the toddler dose. Despite a lower immunogenicity for serotypes 6B and 23F after the primary series of PCV13, responses to the seven common serotypes were comparable between the PCV13 and PCV7 groups when measured after the toddler dose. PCV13 also elicited substantial levels of OPA activity against all 13 serotypes following both the infant series and the toddler dose. In conclusion, PCV13 appeared comparable to PCV7 in safety profile and immunogenicity for common serotypes, demonstrated functional OPA responses for all 13 serotypes, and did not interfere with immune responses to concomitantly administered DTaP-HBV-IPV/Hib vaccine.

UR - http://www.scopus.com/inward/record.url?scp=77953156443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953156443&partnerID=8YFLogxK

U2 - 10.1128/CVI.00062-10

DO - 10.1128/CVI.00062-10

M3 - Article

C2 - 20427630

AN - SCOPUS:77953156443

VL - 17

SP - 1017

EP - 1026

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 6

ER -